The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 19, 2015

Filed:

Feb. 22, 2013
Applicants:

Amylin Pharmaceuticals, Llc, San Diego, CA (US);

Astrazeneca Pharmaceuticals Lp, Wilmington, DE (US);

Inventors:

Mark Fineman, San Diego, CA (US);

Leigh MacConell, San Diego, CA (US);

Kristin Taylor, San Diego, CA (US);

Assignees:

Amylin Pharmaceuticals, LLC, San Diego, CA (US);

Astrazeneca Pharmaceuticals, LP, Wilmington, DE (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/26 (2006.01); A61K 9/50 (2006.01); A61K 38/22 (2006.01);
U.S. Cl.
CPC ...
A61K 38/26 (2013.01); A61K 9/5031 (2013.01); A61K 38/2278 (2013.01);
Abstract

Provided herein are pharmaceutical formulations containing exendins, exendin agonists, or exendin analog agonists that are administered at therapeutic plasma concentration levels over a sustained period of time to lower total cholesterol levels; to lower LDL-cholesterol levels; to lower triglyceride levels; to treat dyslipidemia; to treat and slow the progression of atherosclerosis; and to treat, prevent, and reduce the risk of heart attacks and strokes in patients. In the pharmaceutical formulations and methods of the invention, the exendin may be exendin-4, an exendin-4 agonist, or an exendin-4 analog agonist. The pharmaceutical formulations may be polymer-based pharmaceutical formulations that may be administered once weekly. An exemplary pharmaceutical formulation comprises 5% (w/w) of exenatide, about 2% (w/w) of sucrose, and about 93% (w/w) of a poly(lactide-co-glycolide) polymer, wherein the poly(lactide-co-glycolide) polymer is in the form of microspheres encapsulating the exenatide.


Find Patent Forward Citations

Loading…